Guillain-barre Syndrome
📧 Sign up to get email alerts when something new happens for Guillain-barre Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-24EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH
Authorised status for Privigen (human normal immunoglobulin IVIg) by CSL Behring GmbH in the EMA; therapeutic areas include various immunolo…
-
CLINICAL_TRIALS trial_result · 2023-09-18Clinical Trial Update: Early and Late Prognosis in Patients With Guillain-Barre Syndrome [Phase 4]
A Phase 4 clinical trial evaluating early and late prognosis in patients with Guillain-Barre Syndrome.